Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years old~* Must have measurable or detectable ovarian, fallopian or primary peritoneal cancer~* Must have been treated previously with carboplatin, cisplatin or another organoplatinum compound~Exclusion Criteria:~* Women who are pregnant or nursing~* History of congenital long QT syndrome~* Active bleeding or at risk of a bleeding disorder~* Other significant medical condition or history of medical condition which may put the patient at risk

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine (Type: ACTIVE_COMPARATOR): None
- Gemcitabine + pazopanib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).